NASDAQ:BNOX Bionomics (BNOX) Stock Price, News & Analysis $0.68 +0.01 (+1.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.66▼$0.7050-Day Range$0.65▼$1.2052-Week Range$0.65▼$6.41Volume165,110 shsAverage Volume348,746 shsMarket Capitalization$5.55 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Bionomics alerts: Email Address Bionomics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,223.7% Upside$9.00 Price TargetShort InterestHealthy1.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.99) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBionomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBionomics has only been the subject of 1 research reports in the past 90 days.Read more about Bionomics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.82% of the outstanding shares of Bionomics have been sold short.Short Interest Ratio / Days to CoverBionomics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bionomics has recently decreased by 24.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBionomics does not currently pay a dividend.Dividend GrowthBionomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNOX. Previous Next 1.9 News and Social Media Coverage News SentimentBionomics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bionomics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for BNOX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Bionomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bionomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Bionomics is held by insiders.Percentage Held by InstitutionsOnly 15.90% of the stock of Bionomics is held by institutions.Read more about Bionomics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bionomics are expected to grow in the coming year, from ($2.99) to ($1.45) per share.Price to Book Value per Share RatioBionomics has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bionomics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Bionomics Stock (NASDAQ:BNOX)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Read More BNOX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNOX Stock News HeadlinesJuly 19, 2024 | finanznachrichten.deBionomics Ltd: Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety DisorderJuly 19, 2024 | markets.businessinsider.comBuy Rating Affirmed on Bionomics as BNC210 Enters Critical Phase 3 Trial for Social Anxiety DisorderJuly 27, 2024 | True Market Insiders (Ad)Amazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…July 19, 2024 | americanbankingnews.comBionomics (NASDAQ:BNOX) Receives Buy Rating from HC WainwrightJuly 18, 2024 | globenewswire.comBionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety DisorderMay 31, 2024 | globenewswire.comBionomics Limited Announces Private Placement of up to $70.0 MillionMay 20, 2024 | globenewswire.comBionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual MeetingApril 17, 2024 | finance.yahoo.comBionomics Limited (BNOX) Stock Historical Prices & Data - Yahoo FinanceJuly 27, 2024 | True Market Insiders (Ad)Amazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Bionomics’ BNC210 Following Promising PTSD Study ResultsMarch 21, 2024 | msn.comBionomics Reveals Detailed Data From PTSD Trial, Stock SoarsMarch 21, 2024 | globenewswire.comBionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress DisorderMarch 20, 2024 | finance.yahoo.comBionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)February 22, 2024 | globenewswire.comBionomics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 22, 2024 | benzinga.comBionomics Stock (NASDAQ:BNOX), Short Interest ReportJanuary 22, 2024 | finanznachrichten.deBionomics Ltd: Bionomics Provides a Review of 2023 and of 2024 PlansJanuary 22, 2024 | finance.yahoo.comBionomics Provides a Review of 2023 and of 2024 PlansDecember 7, 2023 | morningstar.comBionomics Ltd ADR BNOXSee More Headlines Receive BNOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Estimated)10/04/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNOX CUSIPN/A CIK1191070 Webwww.bionomics.com.au Phone088-150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,223.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio3.81 Quick RatioN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales554.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.25Miscellaneous Outstanding Shares8,160,000Free Float8,038,000Market Cap$5.55 million OptionableNot Optionable Beta-0.11 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Spyridon Papapetropoulos M.D. (Age 51)Ph.D., CEO, President & Director Comp: $516.25kMr. Adrian Hinton BEC (Age 71)F.C.A., Financial Controller Comp: $200.7kMr. Timothy M. Cunningham CPA (Age 61)M.B.A., Chief Financial Officer Prof. Paul Rolan D.C.P.S.A.F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical NeuroscienceDr. Julie Kerner Ph.D.Senior Vice President of Business OperationsMs. Suzanne Irwin B.Com.FCIS, Company SecretaryMore ExecutivesKey CompetitorsMEI PharmaNASDAQ:MEIPBrainstorm Cell TherapeuticsNASDAQ:BCLIHCW BiologicsNASDAQ:HCWBCara TherapeuticsNASDAQ:CARATherapeuticsMDNASDAQ:TXMDView All Competitors BNOX Stock Analysis - Frequently Asked Questions How have BNOX shares performed this year? Bionomics' stock was trading at $1.48 on January 1st, 2024. Since then, BNOX stock has decreased by 54.1% and is now trading at $0.6799. View the best growth stocks for 2024 here. When did Bionomics IPO? Bionomics (BNOX) raised $20 million in an IPO on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share. How do I buy shares of Bionomics? Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BNOX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.